Drugs / carboplaitin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04976647 Comparator | Jan 2022 → Jan 2023 | non-small cell squamous lung carcinoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carboplaitin | “carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle” NCT04976647 ↗ |
| Route | Intravenous | “carboplaitin (AUC5 or 6) IV Q3W” NCT04976647 ↗ |